Cargando…

Cross-validation of optimized composites for preclinical Alzheimer's disease

INTRODUCTION: We discuss optimization and validation of composite end points for presymptomatic Alzheimer's disease clinical trials. Optimized composites offer hope of substantial gains in statistical power or reduction in sample size. But there is tradeoff between optimization and face validit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Donohue, Michael C., Sun, Chung-Kai, Raman, Rema, Insel, Philip S., Aisen, Paul S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2016
Materias:	Featured Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5527287/ https://www.ncbi.nlm.nih.gov/pubmed/28758145 http://dx.doi.org/10.1016/j.trci.2016.12.001

Ejemplares similares

The relative efficiency of time-to-progression and continuous measures of cognition in presymptomatic Alzheimer's disease
por: Li, Dan, et al.
Publicado: (2019)

Optimizing the preclinical Alzheimer's cognitive composite with semantic processing: The PACC5
por: Papp, Kathryn V., et al.
Publicado: (2017)

Biomarkers and cognitive endpoints to optimize trials in Alzheimer's disease
por: Insel, Philip S, et al.
Publicado: (2015)

Neuroanatomical spread of amyloid β and tau in Alzheimer’s disease: implications for primary prevention
por: Insel, Philip S, et al.
Publicado: (2020)

Preclinical Alzheimer's disease and longitudinal driving decline
por: Roe, Catherine M., et al.
Publicado: (2016)

Disparities by Race and Ethnicity Among Adults Recruited for a Preclinical Alzheimer Disease Trial
por: Raman, Rema, et al.
Publicado: (2021)

Clinical and cognitive characteristics of preclinical Alzheimer's disease in the Japanese Alzheimer's Disease Neuroimaging Initiative cohort
por: Ihara, Ryoko, et al.
Publicado: (2018)

Safety and tolerability of lumbar puncture for the evaluation of Alzheimer's disease
por: Baldaranov, Dobri, et al.
Publicado: (2023)

Early-stage Alzheimer disease: getting trial-ready
por: Aisen, Paul S., et al.
Publicado: (2022)

The effect of diagnostic criteria on outcome measures in preclinical and prodromal Alzheimer's disease: Implications for trial design
por: Bertens, Daniela, et al.
Publicado: (2017)

Contribution of Alzheimer's biomarkers and risk factors to cognitive impairment and decline across the Alzheimer's disease continuum
por: Tosun, Duygu, et al.
Publicado: (2021)

A simulation study comparing slope model with mixed-model repeated measure to assess cognitive data in clinical trials of Alzheimer's disease
por: Chen, Yun-Fei, et al.
Publicado: (2018)

African Americans are less likely to enroll in preclinical Alzheimer's disease clinical trials
por: Zhou, Yan, et al.
Publicado: (2016)

Effects of traumatic brain injury and posttraumatic stress disorder on development of Alzheimer's disease in Vietnam Veterans using the Alzheimer's Disease Neuroimaging Initiative: Preliminary report
por: Weiner, Michael W., et al.
Publicado: (2017)

Latent class analysis identifies functional decline with Amsterdam IADL in preclinical Alzheimer's disease
por: Villeneuve, Sarah-Christine, et al.
Publicado: (2019)

Preclinical and clinical biomarker studies of CT1812: A novel approach to Alzheimer's disease modification
por: Izzo, Nicholas J., et al.
Publicado: (2021)

The Trial-Ready Cohort for Preclinical/Prodromal Alzheimer’s Disease (TRC-PAD) Project: An Overview
por: Aisen, P.S., et al.
Publicado: (2020)

Targeting butyrylcholinesterase for preclinical single photon emission computed tomography (SPECT) imaging of Alzheimer's disease
por: DeBay, Drew R., et al.
Publicado: (2017)

Delayed-start analysis: Mild Alzheimer's disease patients in solanezumab trials, 3.5 years
por: Liu-Seifert, Hong, et al.
Publicado: (2015)

Demonstration of safety of intravenous immunoglobulin in geriatric patients in a long-term, placebo-controlled study of Alzheimer's disease
por: Gelmont, David, et al.
Publicado: (2016)

Amyloid beta, tau, synaptic, neurodegeneration, and glial biomarkers in the preclinical stage of the Alzheimer's continuum
por: Milà‐Alomà, Marta, et al.
Publicado: (2020)

Cerebrospinal fluid neurogranin/β-site APP-cleaving enzyme 1 predicts cognitive decline in preclinical Alzheimer's disease
por: Kirsebom, Bjørn-Eivind, et al.
Publicado: (2018)

Determining clinically meaningful decline in preclinical Alzheimer disease
por: Insel, Philip S., et al.
Publicado: (2019)

Alzheimer's disease Archimedes condition-event simulator: Development and validation
por: Kansal, Anuraag R., et al.
Publicado: (2018)

A composite measure of cognitive and functional progression in Alzheimer's disease: Design of the Capturing Changes in Cognition study
por: Jutten, Roos J., et al.
Publicado: (2017)

The Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease Trial: A study of crenezumab versus placebo in preclinical PSEN1 E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal-dominant Alzheimer's disease, including a placebo-treated noncarrier cohort
por: Tariot, Pierre N., et al.
Publicado: (2018)

Sex-specific composite scales for longitudinal studies of incipient Alzheimer’s disease
por: Banks, Sarah J., et al.
Publicado: (2019)

APOE effects on regional tau in preclinical Alzheimer’s disease
por: Young, Christina B., et al.
Publicado: (2023)

The Alzheimer's Disease Cooperative Study Prevention Instrument Project: Longitudinal Outcome of Behavioral Measures as Predictors of Cognitive Decline
por: Banks, Sarah Jane, et al.
Publicado: (2014)

Development of Written Materials for Participants in an Alzheimer's Disease and Related Dementias Screening Trial
por: Head, Katharine J, et al.
Publicado: (2022)

Intranasal insulin modulates cerebrospinal fluid markers of neuroinflammation in mild cognitive impairment and Alzheimer’s disease: a randomized trial
por: Kellar, Derek, et al.
Publicado: (2022)

A blood-based nutritional risk index explains cognitive enhancement and decline in the multidomain Alzheimer prevention trial
por: Bowman, Gene L., et al.
Publicado: (2019)

Predicting the course of Alzheimer’s progression
por: Iddi, Samuel, et al.
Publicado: (2019)

Applications of Neuroimaging to Disease-Modification Trials in Alzheimer’s Disease
por: Fleisher, Adam S., et al.
Publicado: (2009)

Virus outbreak crosses boundaries
por: Gross, Michael
Publicado: (2020)

Online study partner-reported cognitive decline in the Brain Health Registry
por: Nosheny, Rachel L., et al.
Publicado: (2018)

The AHEAD 3–45 Study: Design of a prevention trial for Alzheimer’s disease
por: Rafii, Michael S., et al.
Publicado: (2023)

Proof of concept demonstration of optimal composite MRI endpoints for clinical trials
por: Edland, Steven D., et al.
Publicado: (2016)

Active Aβ immunotherapy CAD106 in Alzheimer's disease: A phase 2b study
por: Vandenberghe, Rik, et al.
Publicado: (2016)

Making an IMPACTT: A framework for developing a dentist's ability to provide comprehensive dental care
por: Aulakh, Raman
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_v2a72reug5qi1k0cdtlsj7j7cc